Evidence map›Paper›PMID 28042071›Full record

ReviewJournal of pain and symptom management2017

The Edmonton Symptom Assessment System 25 Years Later: Past, Present, and Future Developments.

David Hui, Eduardo Bruera

2 registry-linked trialsAbstract readReview
In one paragraph

Review in Journal of pain and symptom management, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 393 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
393citing papers in PubMed, 3 pooled it
26.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06032091 unknown statusnot on this mapstarted 2023, after this paper: background citation

Digital Phenotyping for Changes in Activity at the End of Life in People With Dementia: an Observational Trial Based on Sensing Technology

TypeobservationalSponsorUniversity of BergenRan2023 to 2026Enrolled50ConditionsDementiaArmsNo intervention
NCT07653698 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

Evaluation of Cancer Cachexia and Analysis of Gut Microbiota in Patients With Breast Cancer Receiving Home Care

TypeinterventionalSponsorFondazione ANT Franco Pannuti ETSRan2026 to 2028Enrolled140ConditionsBreast Cancer, Cancer CachexiaArmsProbiotic Mixture, Placebo
3 · Its place in the literature

Who cites it

393 citing papers in PubMed, 3 syntheses or guidelines pooled it, 744 citations in OpenAlex.

  1. Pooled it
  2. Cannabis and Cannabinoids in Adults With Cancer: ASCO Guideline.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024
    Guideline
  3. Quality of life in patients with malignant spinal cord compression: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023
    Pooled it
  4. Behavioral speech therapy intervention can improve the postoperative pain and performance status of lung cancer patients undergoing thoracoscopic surgery.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Trial
  5. Predictive biomarkers of placebo response in patients with cancer: an exploratory analysis of the ABCD randomized clinical trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Trial
  6. Trial
  7. Trial
  8. Trial
  9. Medicinal cannabis for symptom control in advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of 1:1 tetrahydrocannabinol and cannabidiol.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Trial
  10. Trial
  11. Article
  12. Integrative oncology consultation and patient referral to complementary therapies: results from the prospective study THERAC.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Observational
  13. Article
  14. Article
  15. Article
  16. Article
  17. Symptoms experienced during the first 4 months of chemotherapy administration: a longitudinal cohort study in an Australian cancer treatment unit.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  18. Article
  19. Associations of symptom burden with patient-reported outcomes and clinical outcomes among early phase cancer clinical trial participants.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  20. Article

333 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

David HuiDepartment of Palliative Care and Rehabilitation Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Electronic address: dhui@mdanderson.org.
Eduardo BrueraDepartment of Palliative Care and Rehabilitation Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
The University of Texas MD Anderson Cancer Center · US

Funding

Adjuvant Lorazepam for Agitated Delirium in the Palliative Care UnitR21CA186000 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HUI, DAVID · 2015 to 2016
$399k
NCI NIH HHS R21 CA186000
6 · The paper itself

Abstract

contextRoutine symptom assessment represents the cornerstone of symptom management. Edmonton Symptom Assessment System (ESAS) is one of the first quantitative symptom assessment batteries that allows for simple and rapid documentation of multiple patient-reported symptoms at the same time.

objectivesTo discuss the historical development of ESAS, its current uses in different settings, and future developments.

methodsNarrative review.

resultsSince its development in 1991, ESAS has been psychometrically validated and translated into over 20 languages. We will discuss the variations, advantages, and limitations with ESAS. From the clinical perspective, ESAS is now commonly used for symptom screening and longitudinal monitoring in patients seen by palliative care, oncology, nephrology, and other disciplines in both inpatient and outpatient settings. From the research perspective, ESAS has offered important insights into the nature of symptom trajectory, symptom clusters, and symptom modulators. Furthermore, multiple clinical studies have incorporated ESAS as a study outcome and documented the impact of various interventions on symptom burden. On the horizon, multiple groups are actively investigating further refinements to ESAS, such as incorporating it in electronic health records, using ESAS as a trigger for palliative care referral, and coupling ESAS with personalized symptom goals to optimize symptom response assessment.

conclusionESAS has evolved over the past 25 years to become an important symptom assessment instrument in both clinical practice and research. Future efforts are needed to standardize this tool and explore its full potential to support symptom management.

Indexed as

Symptom AssessmentHumansSeverity of Illness IndexClinical trialdyspneafatigueneoplasmspainpalliative carepersonalized medicinesurveys and questionnairessymptom assessment

Identifiers

PMID28042071
PMCPMC5337174
OpenAlexW2563130015

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.